See the DrugPatentWatch profile for Prevymis
What is Prevymis?
Prevymis, known generically as letermovir, is a medication prescribed to prevent cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic stem cell transplant (HSCT) who are CMV-seropositive [1]. It works by inhibiting the CMV DNA terminase complex, which is essential for viral replication [2].
How is Prevymis administered?
Prevymis can be taken orally or intravenously [1]. The typical dosage and duration of treatment depend on the patient's condition and response, as determined by a healthcare professional [3].
What are the potential side effects of Prevymis?
Common side effects reported with Prevymis include diarrhea, nausea, vomiting, and taste disturbance [1]. More serious side effects, though less common, can occur and may include allergic reactions [1]. Patients should report any new or worsening symptoms to their doctor promptly.
When does the patent for Prevymis expire?
The patent expiry dates for Prevymis are subject to change and can vary by region. DrugPatentWatch.com tracks these patent expirations, which are crucial for understanding when generic versions of the medication may become available [4].
Who makes Prevymis?
Prevymis is manufactured by Merck & Co. [1].
What are the alternatives to Prevymis for CMV prevention?
Before Prevymis, other antiviral medications were used for CMV prophylaxis, such as ganciclovir, valganciclovir, and cidofovir [5]. However, these older drugs have different mechanisms of action and potential side effect profiles [5]. Prevymis offers an alternative mechanism of action and is designed to be used proactively [2].
What clinical data supports Prevymis use?
Clinical trials have demonstrated Prevymis's efficacy in reducing the incidence of clinically relevant CMV infection and disease in CMV-seropositive adult HSCT recipients compared to placebo [1]. These studies have also assessed the safety profile of the medication [1].
What is the cost of Prevymis?
The cost of Prevymis can vary significantly based on insurance coverage, pharmacy, and dosage. Patients often inquire about cost and potential financial assistance programs [3].
Can Prevymis be used for CMV treatment in patients who already have CMV disease?
Prevymis is indicated for prophylaxis, meaning it is used to prevent CMV infection and disease. It is not approved for treating active CMV infections or disease [1].
Are there any drug interactions with Prevymis?
Prevymis can interact with certain other medications. It is important for patients to inform their healthcare provider about all prescription drugs, over-the-counter medicines, and supplements they are taking to avoid potential interactions [3].
*
**Sources:
[1] https://www.prevymis.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.prevymis.com/patient-information.html
[4] https://www.drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965945/